Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has entered into a joint research agreement with the National Cerebral and Cardiovascular Center to conduct a joint research study. The study will examine behavioral changes toward salt reduction through use of the nutrition monitoring app Vivoo by outpatients with cardiovascular disease who have heart disease or hypertension and are participating in cardiac rehabilitation.

This will be an exploratory clinical trial using the nutritional monitoring app Vivoo, aiming to raise awareness about salt reduction among cardiac patients. Vivoo measures nutritional status using artificial intelligence and image-processing technology by scanning urine-soaked test strips with a dedicated app. Users will receive dietary and lifestyle advice supervised by registered dietitians, tailored to their measurement results. By enabling frequent salt-intake measurement at home, the goal is to encourage behavioral change and contribute to user lifestyle improvements.

About Otsuka

Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide.
For further information, please visit www.otsuka.co.jp/en/